Log in to save to my catalogue

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell the...

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell the...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2545986807

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

About this item

Full title

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Publisher

London: Elsevier Ltd

Journal title

The Lancet (British edition), 2021-07, Vol.398 (10297), p.314-324

Language

English

Formats

Publication information

Publisher

London: Elsevier Ltd

More information

Scope and Contents

Contents

CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.
This single-arm, open-label, phase 1b/2 study done a...

Alternative Titles

Full title

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2545986807

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2545986807

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(21)00933-8

How to access this item